Targeting translation: eIF4E as an emerging anticancer drug target.
Wuhu, China. In Expert Rev Mol Med, Dec 2015
The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumour growth, metastasis and therapy resistance.
5' UTR m(6)A Promotes Cap-Independent Translation.
New York City, United States. In Cell, Dec 2015
A single 5' UTR m(6)A directly binds eukaryotic initiation factor 3 (eIF3), which is sufficient to recruit the 43S complex to initiate translation in the absence of the cap-binding factor eIF4E.
eIF4F: a retrospective.
Cleveland, United States. In J Biol Chem, Nov 2015
The regulation of translation exhibited through the mammalian target of rapamycin (mTOR) pathway is predominately seen as the phosphorylation of 4E-BP, an inhibitor of protein synthesis that functions by binding to the cap binding subunit of eIF4F (eIF4E).
Signalling to eIF4E in cancer.
Montréal, Canada. In Biochem Soc Trans, Nov 2015
The eukaryotic translation initiation factor 4E (eIF4E), as part of the eIF4F complex, interacts first with the mRNA and facilitates the recruitment of the 40S ribosomal subunit.
Targeting the translation machinery in cancer.
Montréal, Canada. In Nat Rev Drug Discov, Apr 2015
In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.